Tathagata Mukherjee1, Helena Boshoff. 1. Tuberculosis Research Section, LCID, NIAID, NIH, Room 2W20G, Building 33, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Abstract
Tuberculosis remains a leading cause of death resulting from an infectious agent, and the spread of multi- and extensively drug-resistant strains of Mycobacterium tuberculosis poses a threat to management of global health. New drugs that effectively shorten the duration of treatment and are active against drug-resistant strains of this pathogen are urgently required to develop effective chemotherapies to combat this disease. Two nitroimidazoles, PA-824 and OPC-67683, are currently in Phase II clinical trials for the treatment of TB and the outcome of these may determine the future directions of drug development for anti-tubercular nitroimidazoles. In this review we summarize the development of these nitroimidazoles and alternative analogs in these series that may offer attractive alternatives to PA-824 and OPC-67683 for further development in the drug-discovery pipeline. Lastly, the potential pitfalls in the development of nitroimidazoles as drugs for TB are discussed.
Tuberculosis remains a leading cause of pan class="Disease">death resulting from an infectious agent, and the spread of multi- and extensively drug-resistant strains of Mycobacterium tuberculosis poses a threat to management of global health. New drugs that effectively shorten the duration of treatment and are active against drug-resistant strains of this pathogen are urgently required to develop effective chemotherapies to combat this disease. Two nitroimidazoles, PA-824 and OPC-67683, are currently in Phase II clinical trials for the treatment of TB and the outcome of these may determine the future directions of drug development for anti-tubercular nitroimidazoles. In this review we summarize the development of these nitroimidazoles and alternative analogs in these series that may offer attractive alternatives to PA-824 and OPC-67683 for further development in the drug-discovery pipeline. Lastly, the potential pitfalls in the development of nitroimidazoles as drugs for TB are discussed.
Authors: Lucila Garcia-Contreras; Jean C Sung; Pavan Muttil; Danielle Padilla; Martin Telko; Jarod L Verberkmoes; Katharina J Elbert; Anthony J Hickey; David A Edwards Journal: Antimicrob Agents Chemother Date: 2010-01-19 Impact factor: 5.191
Authors: Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Alexander Arena; Francisco Arrieta; Joseph C J Rebolledo; Diane K Smith Journal: Antimicrob Agents Chemother Date: 2014-09-02 Impact factor: 5.191
Authors: A M Upton; S Cho; T J Yang; Y Kim; Y Wang; Y Lu; B Wang; J Xu; K Mdluli; Z Ma; S G Franzblau Journal: Antimicrob Agents Chemother Date: 2014-10-20 Impact factor: 5.191
Authors: Matthew W Carroll; Doosoo Jeon; James M Mountz; Jong Doo Lee; Yeon Joo Jeong; Nadeem Zia; Myungsun Lee; Jongseok Lee; Laura E Via; Soyoung Lee; Seok-Yong Eum; Sung-Joong Lee; Lisa C Goldfeder; Ying Cai; Boyoung Jin; Youngran Kim; Taegwon Oh; Ray Y Chen; Lori E Dodd; Wenjuan Gu; Veronique Dartois; Seung-Kyu Park; Cheon Tae Kim; Clifton E Barry; Sang-Nae Cho Journal: Antimicrob Agents Chemother Date: 2013-06-03 Impact factor: 5.191